Introduction To assess the efficacy, durability, and safety of faricimab compared with aflibercept over 1 year in patients with diabetic macular edema (DME) from the China RHINE subpopulation. Methods RHINE was a phase 3 global, active comparator-controlled trial. The China RHINE subpopulation included patients from mainland China, Hong Kong, and Taiwan. Patients with DME were randomized to faricimab 6.0 mg every 8 weeks (Q8W), faricimab 6.0 mg treat-and-extend (T there were no new safety signals. Conclusions Visual and anatomic improvements with faricimab in the China RHINE subpopulation were in keeping with the global findings. Faricimab offers durable treatment for patients with DME in China. Trial registration RHINE (NCT03622593).
Li et al. (2026) studied this question.